Health and nutrition claims for infant formula: international cross sectional survey

• Published in: BMJ (Online) 2023-02, Vol.380, p.e071075
• Main Authors: Cheung, Ka Yan, Petrou, Loukia, Helfer, Bartosz, Porubayeva, Erika, Dolgikh, Elena, Ali, Sana, Ali, Insaf, Archibald-Durham, Lindsay, Brockway, Meredith (Merilee), Bugaeva, Polina, Chooniedass, Rishma, Comberiati, Pasquale, Cortés-Macías, Erika, D’Elios, Sofia, Feketea, Gavriela, Hsu, Peter, Kana, Musa Abubakar, Kriulina, Tatiana, Kunii, Yuzuka, Madaki, Comfort, Omer, Rihab, Peroni, Diego, Prokofiev, Jana, Simpson, Melanie Rae, Shimojo, Naoki, Siziba, Linda P, Genuneit, Jon, Thakor, Sohini, Waris, Marium, Yuan, Quan, Zaman, Sadia, Young, Bridget E, Bugos, Brighid, Greenhawt, Matthew, Levin, Michael E, Zheng, Jonathan, Boyle, Robert J, Munblit, Daniel
• Format: Article
• Language: English
• Subjects: Archives & records; Babies; Baby foods; Bias; Breastfeeding & lactation; Clinical trials; Cross-Sectional Studies; Data collection; Food; Humans; Immune system; Infant; Infant Formula; Infants; Ingredients; Marketing; Nervous system; Nutrition; Polyunsaturated fatty acids; Prebiotics; Probiotics; Reviews; Surveys; Systematic Reviews as Topic
• ISSN: 1756-1833; 0959-8138; 1756-1833
• DOI: 10.1136/bmj-2022-071075

AbstractObjectivesTo review available health and nutrition claims for infant formula products in multiple countries and to evaluate the validity of the evidence used for substantiation of claims.DesignInternational cross sectional survey.SettingPublic facing and healthcare professional facing company owned or company managed formula industry websites providing information about products marketed for healthy infants delivered at full term in 15 countries: Australia, Canada, Germany, India, Italy, Japan, Nigeria, Norway, Pakistan, Russia, Saudi Arabia, South Africa, Spain, the United Kingdom, and the United States in 2020-22.Main outcome measuresNumber and type of claims made for each product and ingredient. References cited were reviewed and risk of bias was assessed for registered clinical trials using the Cochrane risk of bias tool, and for systematic reviews using the Risk Of Bias in Systematic reviews tool.Results757 infant formula products were identified, each with a median of two claims (range from 1 (Australia) to 4 (US)), and 31 types of claims across all products. Of 608 products with ≥1 claims, the most common claim types were “helps/supports development of brain and/or eyes and/or nervous system” (323 (53%) products, 13 ingredients), “strengthens/supports a healthy immune system” (239 (39%) products, 12 ingredients), and “helps/supports growth and development” (224 (37%) products, 20 ingredients). 41 groups of ingredients were associated with ≥1claims, but many claims were made without reference to a specific ingredient (307 (50%) products). The most common groups of ingredients cited in claims were long chain polyunsaturated fatty acids (278 (46%) products, 9 different claims); prebiotics, probiotics, or synbiotics (225 (37%) products, 19 claims); and hydrolysed protein (120 (20%) products, 9 claims). 161/608 (26%) products with ≥1 claims provided a scientific reference to support the claim—266 unique references were cited for 24 different claim types for 161 products. The reference types most frequently cited were clinical trials (50%, 134/266) and reviews (20%, 52/266). 28% (38/134) of referenced clinical trials were registered, 14% (19/134) prospectively. 58 claims referred to 32 registered clinical trials, of which 51 claims (27 trials) related to a randomised comparison. 46 of 51 claims (90%) referenced registered clinical trial outcomes at high risk of bias, and all cited systematic reviews and pooled analyses, carried a high risk of bias